Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Single arm, prospective, exploratory clinical study of Disitamab Vedotin combined with
Fruquintinib for advanced colorectal cancer with HER2 expression or mutation that has
received at least two standard treatment failures